Joshua Levine Buys 10,000 Shares of Edap Tms (NASDAQ:EDAP) Stock

Edap Tms S.A. (NASDAQ:EDAP) Director Joshua Levine acquired 10,000 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $4.22 per share, with a total value of $42,200.00. Following the purchase, the director directly owned 35,000 shares in the company, valued at $147,700. This represents a 40.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Edap Tms Stock Performance

NASDAQ:EDAP opened at $4.13 on Friday. The company has a fifty day moving average of $3.70 and a 200-day moving average of $3.43. The firm has a market capitalization of $154.79 million, a P/E ratio of -5.10 and a beta of -0.10. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. Edap Tms S.A. has a twelve month low of $1.21 and a twelve month high of $5.05.

Edap Tms (NASDAQ:EDAP) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The company had revenue of $20.48 million during the quarter, compared to the consensus estimate of $19.46 million. Edap Tms had a negative net margin of 41.47% and a negative return on equity of 137.61%. As a group, sell-side analysts anticipate that Edap Tms S.A. will post -0.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EDAP. Wall Street Zen lowered shares of Edap Tms from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. HC Wainwright decreased their price target on shares of Edap Tms from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $6.00.

Hedge Funds Weigh In On Edap Tms

Hedge funds have recently added to or reduced their stakes in the stock. Financial Planning Navigators CORP acquired a new position in Edap Tms during the 4th quarter valued at about $33,000. SmartHarvest Portfolios LLC acquired a new position in Edap Tms during the 1st quarter valued at about $38,000. Lido Advisors LLC acquired a new position in Edap Tms during the 1st quarter valued at about $40,000. Kovack Advisors Inc. acquired a new position in Edap Tms during the 4th quarter valued at about $53,000. Finally, Leonteq Securities AG acquired a new position in Edap Tms during the 4th quarter valued at about $313,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

About Edap Tms

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.